The Governing Council of the University of Toronto

Hemostemix Inc. plans to up-list its shares on the OTCQB Venture Market to enhance liquidity, targeting investors in the USA, Europe, and Canada. The company highlights ACP-01 therapy's success in treating conditions like heart failure and vascular dementia, showcasing patient testimonials and clinical trial results.

Research led by Dr. Geoffrey Anderson and Dr. Husam Abdel-Qadir analyzed OHIP data from 1998-2012, tracking 100,000 Ontario women. Findings reveal breast cancer treatments can lead to heart disease, with risk of death from cardiovascular causes increasing with age and pre-existing conditions.

Hemostemix's social media campaign for "Your Fountain of Youth"™ regenerative medicine is gaining traction, sharing patient success stories and educating on ACP-01 treatment for cardiovascular diseases. ACP-01, derived from patients' blood, has shown significant improvements in cardiac function and ulcer healing.

AI/ML Innovations Inc. acquires Quantum Sciences Ltd., enhancing AI-driven digital healthcare solutions, particularly in cardiovascular disease. The acquisition leverages Quantum's medical expertise and AI/ML's signal processing capabilities for cardio-focused applications, aiming to improve patient outcomes and medical workflows.

GLP-1 agonists like Ozempic impact brain function, potentially reducing food noise, slowing brain aging, aiding addiction recovery, and affecting mental health. Research suggests these drugs may lower risks of dementia and Parkinson's, improve insulin signaling in the brain, and reduce cravings by acting on brain receptors. However, effects on mental health vary, with some reporting improved symptoms and others experiencing increased depression or anxiety. Fatigue and brain fog are noted side effects, possibly linked to reduced calorie intake and blood sugar levels.

Two studies identify DDX53 gene variants on the X chromosome as contributors to autism spectrum disorder (ASD), particularly in males. The research, published in the American Journal of Human Genetics, highlights the gene's role in brain development and suggests new areas for exploration in ASD. The studies also found 59 genetic variants on the X chromosome associated with ASD, including DDX53 and FGF13, indicating the need for further investigation and new research models.

The Transdermal Drug Delivery Pipeline Report, 2024 Update, offers comprehensive insights into pipeline products, development stages, clinical trials, and key companies shaping the transdermal drug delivery market.

The global targeted protein degradation market is projected to grow from USD 0.548 billion in 2023 to USD 4.37 billion by 2034, driven by precision medicine, drug discovery investments, and technological advancements. PROTACs lead the market, with molecular glues expected to grow fastest. Therapy development dominates applications, particularly in cancer and neurodegenerative diseases. Pharmaceutical & biotechnology companies are the largest end-users. North America leads in revenue, while Asia-Pacific shows the highest growth rate.

Alice Cheng, MD, discussed diabetes and dementia connection at WCIRDC, emphasizing inflammation, brain insulin resistance, and metabolic disturbances. Certain diabetes drugs may protect cognitive function, but larger trials are needed. Lifestyle factors and glycemic control are crucial, with routine cognitive assessments recommended. GLP-1 RAs show promise in managing CKD and HFpEF.

Targeted NGS, using methods like hybrid capture or amplicon enrichment, is crucial for cancer diagnosis and treatment selection. It identifies genetic mutations and fusions, with amplicon methods offering speed and sensitivity, especially for small samples. The CANTRK study highlighted the importance of method choice for detecting NTRK gene fusions, recommending hybrid capture or single-primer kits for comprehensive detection.